Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

Radiotherapy and Oncology

Volumn 44, Issue 3, 1997, Pages 213-221

  Zagars, Gunar K ^a   Pollack, Alan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RELAPSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; HALF-LIFE; HUMANS; KINETICS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030827106     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)00123-0     Document Type: Article

References (26)

1. Altman, D.G. Practical Statistics for Medical Research, pp. 122-395. Chapman and Hall, London, 1991.
2. Carter, H.B., Pearson, J.D., Metter, E.J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J. Am. Med. Assoc. 267: 2215-2220, 1992.
3. Daniell, J., Seckel, J., Dory, F., Smith, R.B. and DeKernion, J.B. Detectable prostate-specific antigen levels following radical prostatectomy: relationship of doubling rime to clinical outcome (abstract). J. Urol. 149: 447A, 1993.
4. Glantz, S.A. and Slinker, B.K. Primer of Applied Regression and Analysis of Variance, pp. 464-511. McGraw-Hill, New York, 1990.
5. Hanks, G.E., D'Amico, A., Epstein, B. and Schultheiss, T. Prostate-specific antigen doubling time in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int. J. Radiat. Oncol. Biol. Phys. 27: 125-127, 1993.
6. Hanks, G.E., Hanlon, A.L., Lee, W.R., Slivjak, A. and Schultheiss, T.E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int. J. Radiat. Oncol. Biol. Phys. 34: 549-553, 1996.
7. Harris, E.K. and Albert, A. Survivorship Analysis for Clinical Studies, pp. 5-123. Marcel Dekker, New York, 1991.
8. Kaplan, I.D., Cox, R.S. and Bagshaw, M.A. A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. Cancer 68: 400-405, 1991.
9. Kavadi, V.S., Zagars, G.K. and Pollack, A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30: 279-1791, 1994.
10. Meek, A.G., Park, T.L., Oberman, E. and Wielopolski, L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 19: 733-741, 1990.
11. Norusis, M.J. SPSS for Windows: Advanced Statistics. Release 5, pp. 215-232. SPSS, Chicago, IL, 1992.
12. Oesterling, J.E., Chan, D.W., Epstein, J.I. et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J. Urol. 139: 766-772, 1988.
13. Partin, A.W., Pound, C.R., Pearson, J.D. et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649-659, 1994.
14. Pollack, A., Zagars, G.K., El-Naggar, A. and Terry, N.H.A. Relationship of tumor DNA-ploidy to serum prostate specific antigen doubling time after radiotherapy for prostate cancer. Urology 44: 711-718, 1994.
15. Pollack, A., Zagars, G.K., Starkschall, G., Childress, C.H., Kopplin, S., Boyer, A.L. and Rosen, I.I. Conventional versus conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int. J. Radiat. Oncol. Biol. Phys. 34: 555-564, 1996.
16. Ritter, M.A., Messing, E.M., Shanahan, T.G., Potts, S., Chappell, R.J. and Kinsella, T.J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10: 1208-1217, 1992.
17. Schmid, H.P., McNeal, J.E. and Stamey, T.A. Observations on the doubling time of prostate cancer. Cancer 71: 2031-2040, 1993.
18. Stamey, T.A., Ferrari, M.K. and Schmid, H.P. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J. Urol. 150: 1856-1859, 1993.
19. Zagars, G.K., Kavadi, V.S., Pollack, A. and von Eschenbach, A.C. The source of serum prostate-specific antigen in clinically localized prostate cancer - T, N, or M? Int. J. Radiat. Oncol. Biol. Phys. 32: 21-32, 1995.
20. Zagars, G.K., Geara, F.D., Pollack, A. and von Eschenbach, A.C. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer 73: 1904-1912, 1994.
21. Zagars, G.K. and Pollack, A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72: 832-842, 1993.
22. Zagars, G.K., Pollack, A. and von Eschenbach, A.C. Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int. J. Radiat. Oncol. Biol. Phys. 33: 23-35, 1995.
23. Zagars, G.K., Pollack, A., Kavadi, V.S. and von Eschenbach, A.C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32: 293-306, 1995.
24. Zagars, G.K., Pollack, A. and von Eschenbach, A.C. Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49: 327-334, 1997.
25. Zagars, G.K., Sherman, N.E. and Babaian, R.J. Prostate-specific antigen and external beam radiotherapy in prostate cancer. Cancer 67: 412-420, 1991.
26. Zietman, A.L., Tibbs, M.K., Dallow, K.C., Sith, A.F., Althausen, A.F., Zlostecki, R.A. and Shipley, W.U. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother. Oncol. 40: 159-162, 1996.